Evotec SE (EVO) Non-Current Debt (2009 - 2026)
Evotec SE (EVO) posted Non-Current Debt of $349873.8 for Q1 2026, down 12.63% sequentially from $400440.3 in Q4 2025, and down 20.39% YoY from $439465.7 in Q1 2025.
Evotec SE (EVO) Non-Current Debt (2009 - 2026) Analysis & Trends
Evotec SE has reported Non-Current Debt for 9 years, with the latest figure at $349873.8 in Q1 2026.
- Quarterly Non-Current Debt fell 20.39% year-over-year to $349873.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $349873.8 (down 20.39% YoY) and the FY2025 annual result came in at $400440.3, down 99.9% from the prior year.
- Non-Current Debt slipped to $349873.8 in Q1 2026 per EVO's latest filing, from $400440.3 in the prior quarter.
- Over five years, Non-Current Debt peaked at $513.3 million in Q4 2023 and troughed at -$349703.3 in Q2 2022.
- A 5-year average of $119.7 million and a median of $420776.3 in 2025 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt jumped 33.99% in 2022, then slumped 99.9% in 2025.
- Over 5 years, Non-Current Debt stood at $500.2 million in 2022, then grew by 2.62% to $513.3 million in 2023, then fell by 18.25% to $419.7 million in 2024, then plunged by 99.9% to $400440.3 in 2025, then declined by 12.63% to $349873.8 in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $349873.8, $400440.3, and $453294.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | 349,873.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 349,873.83 |
| Dec 31, 2025 | 400,440.28 |
| Sep 30, 2025 | 453,294.10 |
| Jun 30, 2025 | 402,086.80 |
| Mar 31, 2025 | 439,465.75 |
| Dec 31, 2024 | 419.68 Mn |
| Sep 30, 2024 | 457,423.80 |
| Dec 31, 2023 | 513.34 Mn |
| Dec 31, 2022 | 500.22 Mn |
| Sep 30, 2022 | 329,479.85 |
| Jun 30, 2022 | -349,703.29 |
| Mar 31, 2022 | 366,012.29 |
| Dec 31, 2021 | 373.33 Mn |
| Sep 30, 2021 | 374,921.38 |
| Dec 31, 2020 | 394.67 Mn |
| Sep 30, 2010 | 3,873.82 |
| Jun 30, 2010 | 3,824.51 |
| Mar 31, 2010 | 5.01 |
| Dec 31, 2009 | 5,548.09 |
| Jun 30, 2009 | 9.87 Mn |